Fibrin patch - Ethicon/Omrix Biopharmaceuticals

Drug Profile

Fibrin patch - Ethicon/Omrix Biopharmaceuticals

Alternative Names: Evarrest; Fibrin pad; Fibrin sealant patch

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ethicon; OMRIX Biopharmaceuticals
  • Class Antihaemorrhagics; Blood coagulation factors; Blood proteins; Serine endopeptidases
  • Mechanism of Action Fibrin stimulants; Thrombin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 05 Mar 2016 Phase-III clinical trials in Surgical blood loss (In adolescents, In children, In infants, In neonates) in England before March 2016 (Perilesional)
  • 05 Mar 2016 Efficacy data from a phase III trial in Surgical blood loss released by Ethicon
  • 01 Sep 2014 Ethicon completes a phase III trial in Surgical blood loss in USA, United Kingdom, Australia and New Zealand (NCT01993888)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top